# US 2019/0376983 A1 · Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376983 A1
- Document ID: US20190376983A1
- Status: Published application
- Kind: A1
- Application number: 15/990,091
- Filed: 2018-05-25
- Published: 2019-12-12
- Earliest claimed: 2017-05-25
- Assignees: Abbott Laboratories
- Applicants: Abbott Laboratories
- Inventors: Beth McQuiston; Justin Rogers; Jaime Marino; Raj Chandran; Tiaming Zhang; Saul Datwyler
- Web page: https://patentgrep.com/patent/US20190376983A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61B 5/0042: {for the brain}
- A61B 6/03: Computed tomography [CT]
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61B 6/032: {Transmission computed tomography [CT]}
- A61B 6/501: {for diagnosis of the head, e.g. neuroimaging or craniography}
- G01N 2333/914: Hydrolases (3)
- G01N 2333/918: Carboxylic ester hydrolases (3.1.1)
- G01N 2800/28: Neurological disorders
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

## Claims

### Claim 1

A method of aiding in the determination of whether to perform an imaging procedure on a human subject that has sustained or may have sustained an injury to the head, the method comprising:
a) performing an assay on a sample obtained from the subject within about 24 hours after a suspected injury to the head to measure or detect a level of an early biomarker in the sample, said early biomarker comprising ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in the sample; and
b) determining whether to perform an imaging procedure on the subject when the level of the early biomarker in the sample is higher than a reference level of the early biomarker and not performing an imaging procedure on the subject when the level of the early biomarker in the sample is lower than a reference level of the early biomarker,
wherein the reference level is (a) determined by an assay having a sensitivity of between at least about 70% to 100% and a specificity of between at least about 30% to 100%; or (b) between at least about 20 pg/mL to about 200 pg/mL.

### Claim 2 (depends on 1)

The method of claim 1, wherein the reference level is determined by an assay having a sensitivity of at least about 80% and a specificity of at least about 30%.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reference level is between at least about 80 pg/mL to about 150 pg/mL.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has received an imaging procedure before or after the assay is performed.

### Claim 5 (depends on 4)

The method of claim 4, wherein the subject is suspected of having a traumatic brain injury based on the imaging procedure.

### Claim 6 (depends on 1)

The method of claim 1, wherein the imaging procedure is a magnetic resonance imaging (MRI) or a head computerized tomography (CT) scan.

### Claim 7 (depends on 6)

The method of claim 6, wherein the reference level is correlated with a positive MRI scan or positive CT scan.

### Claim 8 (depends on 7)

The method of claim 7, wherein the reference level is correlated with the presence of an intracranial lesion.

### Claim 9 (depends on 1)

The method of claim 1, wherein the reference level is correlated with control subjects that have not sustained a head injury.

### Claim 10 (depends on 1)

The method of claim 1, wherein the reference level for GFAP is between about 20 pg/mL and about 200 pg/mL.

### Claim 11 (depends on 1)

The method of claim 1, wherein the reference level for UCH-L1 is about 80 pg/mL and about 150 pg/mL.

### Claim 12 (depends on 1)

The method of claim 1, wherein the sample is taken within about 0 to about 12 hours after the suspected injury to the head.

### Claim 13

A method of aiding in the determination of whether to perform an imaging procedure on a human subject that has sustained or may have sustained an injury to the head, the method comprising:
a) performing an assay on at least two samples obtained from the subject, the first sample taken from the subject within 24 hours of a suspected injury and the second sample taken from the subject from about 3 to about 6 hours after the first sample is taken;
b) detecting in the at least two samples an early biomarker of traumatic brain injury, said early biomarker comprising ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof; and
c) determining whether to perform an imaging procedure on the subject when the level of the early biomarker decreases or increases by at least an absolute amount from the first sample to the second sample and not performing an imaging procedure on the subject when there is no decrease or increase by at least an absolute amount in the level of the early biomarker from the first sample to the second sample.

### Claim 14 (depends on 13)

The method of claim 13, wherein the subject has received an imaging procedure before or after the assay is performed.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject is suspected as having a traumatic brain injury based on the imaging procedure.

### Claim 16 (depends on 13)

The method of claim 13, wherein the imaging procedure is a magnetic resonance imaging or a head computerized tomography (CT) scan.

### Claim 17 (depends on 16)

The method of claim 16, wherein the absolute amount is correlated with a positive MRI scan or positive CT scan.

### Claim 18 (depends on 17)

The method of claim 17, wherein the absolute amount is correlated with the presence of an intracranial lesion.

### Claim 19 (depends on 18)

The method of claim 18, wherein the absolute amount is determined by an assay having a sensitivity of between at least about 70% to 100% and a specificity of between at least about 30% to 100%.

### Claim 20 (depends on 19)

The method of claim 19, wherein the absolute amount is determined by an assay having (a) a sensitivity of at least about 80% and a specificity of at least about 30%; or (b) a sensitivity of at least about 75% and a specificity of at least about 40%.

### Claim 21 (depends on 19)

The method of claim 19, wherein the absolute amount is between at least about 10 pg/mL and at least about 150 pg/mL.

### Claim 22 (depends on 23)

The method of claim 23, wherein the early biomarker is UCH-L1 and the absolute amount is between at least about 30 pg/mL to about 100 pg/mL, the early biomarker is GFAP and the absolute amount is between at least about 10 pg/mL to about 150 pg/mL, or a combination thereof.

### Claim 23 (depends on 13)

The method of claim 13, wherein the first sample is taken within about 0 to about 12 hours after the suspected injury to the head.

### Claim 24 (depends on 13)

The method of claim 13, wherein the second sample is taken from the subject between about 3 hours to about 6 after the first sample.

### Claim 25 (depends on 1)

The method of claim 1, wherein measuring the level of UCH-L1 is done by an immunoassay or clinical chemistry assay.

### Claim 26 (depends on 1)

The method of claim 1, wherein measuring the level of UCH-L1 comprises:
A. contacting the sample, either simultaneously or sequentially, in any order with:
(1) a UCH-L1-capture antibody, which binds to an epitope on UCH-L1 or UCH-L1 fragment to form a UCH-L1-capture antibody-UCH-L1 antigen complex, and
(2) a UCH-L1-detection antibody which includes a detectable label and binds to an epitope on UCH-L1 that is not bound by the UCH-L1-capture antibody, to form a UCH-L1 antigen-UCH-L1-detection antibody complex,
such that a UCH-L1-capture antibody-UCH-L1 antigen-UCH-L1-detection antibody complex is formed, and
B. measuring the amount or concentration of UCH-L1 in the sample based on the signal generated by the detectable label in the UCH-L1-capture antibody-UCH-L1 antigen-UCH-L1-detection antibody complex.

### Claim 27 (depends on 1)

The method of claim 1, wherein measuring the level of GFAP is done by an immunoassay or clinical chemistry assay.

### Claim 28 (depends on 1)

The method of claim 1, wherein measuring the level of GFAP comprises:
A. contacting the sample, either simultaneously or sequentially, in any order with:
(1) a GFAP-capture antibody, which binds to an epitope on GFAP or GFAP fragment to form a GFAP-capture antibody-GFAP antigen complex, and
(2) a GFAP-detection antibody which includes a detectable label and binds to an epitope on GFAP that is not bound by the GFAP-capture antibody, to form a GFAP antigen-GFAP-detection antibody complex,
such that a GFAP-capture antibody-GFAP antigen-GFAP-detection antibody complex is formed, and
B. measuring the amount or concentration of GFAP in the sample based on the signal generated by the detectable label in the GFAP-capture antibody-GFAP antigen-GFAP-detection antibody complex.

### Claim 29 (depends on 1)

The method of claim 1, wherein the sample is selected from the group consisting of a whole blood sample, a serum sample, a cerebrospinal fluid sample, and a plasma sample.

### Claim 30 (depends on 1)

The method of claim 1, wherein the sample is obtained after the subject sustained an injury to the head caused by physical shaking, blunt impact by an external mechanical or other force that results in a closed or open head trauma, one or more falls, explosions or blasts or other types of blunt force trauma.

### Claim 31 (depends on 1)

The method of claim 1, wherein the sample is obtained after the subject has ingested or been exposed to a chemical, toxin or combination of a chemical and toxin.

### Claim 32 (depends on 31)

The method of claim 31, wherein the chemical or toxin is fire, mold, asbestos, a pesticide, an insecticide, an organic solvent, a paint, a glue, a gas, an organic metal, a drug of abuse or one or more combinations thereof.

### Claim 33 (depends on 1)

The method of claim 1, wherein the sample is obtained from a subject that suffers from an autoimmune disease, a metabolic disorder, a brain tumor, hypoxia, a virus, meningitis, hydrocephalus or combinations thereof.

### Claim 34 (depends on 1)

The method of claim 1, wherein said method can be carried out on any subject without regard to factors selected from the group consisting of the subject's clinical condition, the subject's laboratory values, the subject's classification as suffering from mild, moderate, severe or moderate to severe traumatic brain injury, the subject's exhibition of low or high levels of UCH-L1, and the timing of any event wherein said subject may have sustained an injury to the head.

### Claim 35 (depends on 1)

The method of claim 1, further comprising treating the subject with a mild traumatic brain injury treatment.

### Claim 36 (depends on 1)

The method of claim 1, further comprising monitoring the subject.

### Claim 37 (depends on 1)

The method of claim 1, wherein the sample is a whole blood sample.

### Claim 38 (depends on 1)

The method of claim 1, wherein the sample is a serum sample.

### Claim 39 (depends on 1)

The method of claim 1, wherein the sample is a plasma sample.

### Claim 40 (depends on 37)

The method of claim 37, wherein the assay is an immunoassay.

### Claim 41 (depends on 37)

The method of claim 37, wherein the assay is a clinical chemistry assay.

### Claim 42 (depends on 37)

The method of claim 37, wherein the assay is a single molecule detection assay.
